Keep up to date on Innovation Prize 2018 via
Contact|
Astellas, MD Anderson: Agreement to Research, Develop AML Treatment
07 Apr 2015 / by Admin / in News

Astellas, MD Anderson: Agreement to Research, Develop AML Treatment

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

Source: www.dddmag.com


:  

Comments are closed.